| Trial ID: | L6355 |
| Source ID: | NCT00596687
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
|
| Acronym: |
RABBIT 2-SX
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00596687/results
|
| Conditions: |
Type 2 Diabetes|Inpatient Hyperglycemia
|
| Interventions: |
DRUG: Insulin glargine|DRUG: Regular insulin|DRUG: Insulin glulisine
|
| Outcome Measures: |
Primary: Mean Blood Glucose Concentration, blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment, hospital stay days 2-10 | Secondary: # Participants With Hypoglycemic Events, number of participants in the treatment arms with of hypoglycemic events (\< 70 mg/dl), hospital stay days 2-10
|
| Sponsor/Collaborators: |
Sponsor: Emory University | Collaborators: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
234
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2007-12
|
| Completion Date: |
2013-07
|
| Results First Posted: |
2014-03-12
|
| Last Update Posted: |
2014-03-12
|
| Locations: |
Grady Memorial Hospital, Atlanta, Georgia, 30303, United States|Emory University Hospital, Atlanta, Georgia, 30324, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00596687
|
